Menu
Search
|

Menu

Close
X

Eyenovia Inc EYEN.OQ (NASDAQ Stock Exchange Capital Market)

10.02 USD
+0.53 (+5.58%)
As of 7:09 PM GMT
chart
Previous Close 9.49
Open 9.50
Volume 7,038
3m Avg Volume --
Today’s High 10.10
Today’s Low 9.50
52 Week High 10.60
52 Week Low 8.51
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY16
0
EPS (USD)
FY16
-0.116
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Fredric Eshelman
Chairman of the Board, Since
Salary: --
Bonus: --
Sean Ianchulev
President, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
John Gandolfo
Chief Financial Officer, Since
Salary: --
Bonus: --
Luke Clauson
R & D, Engineering, Since
Salary: --
Bonus: --
Curt Labelle
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

8748 Technology Way
RENO   NV   89521-5925

Phone: +1813.7669539

Eyenovia, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of ophthalmology products utilizing its piezo-print technology to deliver micro-doses of active pharmaceutical ingredients (micro-therapeutics) to the eye. Its product candidates include MicroProst, MicroStat, MicroTears and MicroPine. MicroProst is its proprietary latanoprost prostaglandin micro-formulation product candidate being developed for a first-line indication therapy for chronic angle closure glaucoma (CACG). MicroStat is a fixed combination micro-formulation product candidate that is being developed for mydriasis (eye dilation). MicroStat is designed to achieve adequate pupil dilation while reducing side-effects associated with conventional mydriatic agents. MicroTears is its micro-droplet ocular surface tear replenishment product candidate. MicroPine is its micro-therapeutic formulation of atropine to target myopia (near sightedness) progression.

SPONSORED STORIES